TY - JOUR
T1 - Deletion of the glucocorticoid receptor chaperone FKBP51 prevents glucocorticoid-induced skin atrophy
AU - Baida, Gleb
AU - Bhalla, Pankaj
AU - Yemelyanov, Alexander
AU - Stechschulte, Lance A.
AU - Shou, Weinian
AU - Readhead, Ben
AU - Dudley, Joel T.
AU - Sánchez, Edwin R.
AU - Budunova, Irina
N1 - Funding Information:
This work was supported by R01GM112945, R01AI125366 (to IB and JTD), Foglia family foundation grant (to IB), DK111826 (to ERS), and ADA grant #1-17-PDF-067 (to LAS). We are thankful to NU SDRC pathology and DNA/RNA delivery cores and MD Anderson Science Park Histology Core for technical consultations and support.
Publisher Copyright:
© 2018 Impact Journals LLC. All rights reserved.
PY - 2018/10/1
Y1 - 2018/10/1
N2 - FKBP51 (FK506-binding protein 51) is a known co-chaperone and regulator of theglucocorticoid receptor (GR), which usually attenuates its activity. FKBP51 is one ofthe major GR target genes in skin, but its role in clinical effects of glucocorticoids is notknown. Here, we used FKBP51 knockout (KO) mice to determine FKBP51's role in themajor adverse effect of topical glucocorticoids, skin atrophy. Unexpectedly, we foundthat all skin compartments (epidermis, dermis, dermal adipose and CD34+ stem cells)in FKBP51 KO animals were much more resistant to glucocorticoid-induced hypoplasia.Furthermore, despite the absence of inhibitory FKBP51, the basal level of expressionand glucocorticoid activation of GR target genes were not increased in FKBP51 KO skinor CRISPR/Cas9-edited FKBP51 KO HaCaT human keratinocytes. FKBP51 is known tonegatively regulate Akt and mTOR. We found a significant increase in AktSer473 andmTORSer2448 phosphorylation and downstream pro-growth signaling in FKBP51-deficient keratinocytes in vivo and in vitro. As Akt/mTOR-GR crosstalk is usuallynegative in skin, our results suggest that Akt/mTOR activation could be responsiblefor the lack of increased GR function and resistance of FKBP51 KO mice to the steroidinduced skin atrophy.
AB - FKBP51 (FK506-binding protein 51) is a known co-chaperone and regulator of theglucocorticoid receptor (GR), which usually attenuates its activity. FKBP51 is one ofthe major GR target genes in skin, but its role in clinical effects of glucocorticoids is notknown. Here, we used FKBP51 knockout (KO) mice to determine FKBP51's role in themajor adverse effect of topical glucocorticoids, skin atrophy. Unexpectedly, we foundthat all skin compartments (epidermis, dermis, dermal adipose and CD34+ stem cells)in FKBP51 KO animals were much more resistant to glucocorticoid-induced hypoplasia.Furthermore, despite the absence of inhibitory FKBP51, the basal level of expressionand glucocorticoid activation of GR target genes were not increased in FKBP51 KO skinor CRISPR/Cas9-edited FKBP51 KO HaCaT human keratinocytes. FKBP51 is known tonegatively regulate Akt and mTOR. We found a significant increase in AktSer473 andmTORSer2448 phosphorylation and downstream pro-growth signaling in FKBP51-deficient keratinocytes in vivo and in vitro. As Akt/mTOR-GR crosstalk is usuallynegative in skin, our results suggest that Akt/mTOR activation could be responsiblefor the lack of increased GR function and resistance of FKBP51 KO mice to the steroidinduced skin atrophy.
KW - Akt
KW - FKBP51
KW - Glucocorticoid
KW - Glucocorticoid receptor
KW - Skin atrophy
UR - http://www.scopus.com/inward/record.url?scp=85054501691&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85054501691&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.26194
DO - 10.18632/oncotarget.26194
M3 - Article
C2 - 30410676
AN - SCOPUS:85054501691
SN - 1949-2553
VL - 9
SP - 34772
EP - 34783
JO - Oncotarget
JF - Oncotarget
IS - 78
ER -